Literature DB >> 2020668

Graft-versus-host disease in experimental allogeneic bone marrow transplantation.

R Korngold1, J Sprent.   

Abstract

Considerable progress has been made in defining the relative contributions of CD4+ and CD8+ cells to GVHD. Studies in mice have shown that, in isolation, each T cell subset is able to induce lethal GVHD in irradiated hosts. For hosts differing at the MHC (H-2), CD4+ cells cause GVHD directed to H-2 class II antigens whereas CD8+ cells produce GVHD to H-2 class I antigens. With H-2-matched hosts expressing multiple minor H antigens, induction of lethal GVHD is largely under the control of CD8+ cells. Which particular minor H antigens provide the targets for GVHD in mice is still unclear. Clarifying this question is complicated by the finding that the target antigens for GVHD do not necessarily correlate with the targets for cytotoxicity measured in vitro; moreover, immunodominance occurs when T cells are exposed to multiple minor H antigens in vivo. In terms of clinical application, there is a need to devise animal models for improving the success of HLA-matched bone marrow transplantation. Selectively depleting the marrow inoculum of CD8+ cells and preimmunizing the donor against viral pathogens are two procedures which are currently under study.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2020668     DOI: 10.3181/00379727-197-43217a

Source DB:  PubMed          Journal:  Proc Soc Exp Biol Med        ISSN: 0037-9727


  6 in total

Review 1.  Strategies for the identification of T cell-recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantation.

Authors:  Jenny Zilberberg; Rena Feinman; Robert Korngold
Journal:  Biol Blood Marrow Transplant       Date:  2014-11-20       Impact factor: 5.742

2.  STAT3 signaling in CD4+ T cells is critical for the pathogenesis of chronic sclerodermatous graft-versus-host disease in a murine model.

Authors:  Vedran Radojcic; Maria A Pletneva; Hung-Rong Yen; Sanja Ivcevic; Angela Panoskaltsis-Mortari; Anita C Gilliam; Charles G Drake; Bruce R Blazar; Leo Luznik
Journal:  J Immunol       Date:  2009-12-07       Impact factor: 5.422

Review 3.  From humble beginnings to success in the clinic: Chimeric antigen receptor-modified T-cells and implications for immunotherapy.

Authors:  Amelia E Firor; Alexander Jares; Yupo Ma
Journal:  Exp Biol Med (Maywood)       Date:  2015-05-07

Review 4.  Chimeric antigen receptors: driving immunology towards synthetic biology.

Authors:  Michel Sadelain
Journal:  Curr Opin Immunol       Date:  2016-06-30       Impact factor: 7.486

Review 5.  Graft-versus-host disease and the Th1/Th2 paradigm.

Authors:  W Krenger; J L Ferrara
Journal:  Immunol Res       Date:  1996       Impact factor: 2.829

6.  Bone marrow NK1.1(-) and NK1.1(+) T cells reciprocally regulate acute graft versus host disease.

Authors:  D Zeng; D Lewis; S Dejbakhsh-Jones; F Lan; M García-Ojeda; R Sibley; S Strober
Journal:  J Exp Med       Date:  1999-04-05       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.